267 related articles for article (PubMed ID: 21694929)
21. Vaptans: A new option in the management of hyponatremia.
Aditya S; Rattan A
Int J Appl Basic Med Res; 2012 Jul; 2(2):77-83. PubMed ID: 23776817
[TBL] [Abstract][Full Text] [Related]
22. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
Ferrer E
Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
[TBL] [Abstract][Full Text] [Related]
23. Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.
Bulloch MN; Pinner NA
Expert Rev Clin Pharmacol; 2010 Sep; 3(5):601-12. PubMed ID: 22111741
[TBL] [Abstract][Full Text] [Related]
24. Tolvaptan in the treatment of acute hyponatremia associated with acute kidney injury.
Gopinath S; Janga KC; Greenberg S; Sharma SK
Case Rep Nephrol; 2013; 2013():801575. PubMed ID: 24558627
[TBL] [Abstract][Full Text] [Related]
25. Role of vaptans in the management of hyponatremia.
Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
[TBL] [Abstract][Full Text] [Related]
26. Tolvaptan and its potential in the treatment of hyponatremia.
Dixon MB; Lien YH
Ther Clin Risk Manag; 2008 Dec; 4(6):1149-55. PubMed ID: 19337422
[TBL] [Abstract][Full Text] [Related]
27. Tolvaptan for the treatment of heart failure: a review of the literature.
Ambrosy A; Goldsmith SR; Gheorghiade M
Expert Opin Pharmacother; 2011 Apr; 12(6):961-76. PubMed ID: 21401442
[TBL] [Abstract][Full Text] [Related]
28. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
Friedman B; Cirulli J
J Crit Care; 2013 Apr; 28(2):219.e1-12. PubMed ID: 22884529
[TBL] [Abstract][Full Text] [Related]
29. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
30. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
Ferguson-Myrthil N
Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941
[TBL] [Abstract][Full Text] [Related]
31. Vasopressin antagonists: role in the management of hyponatremia.
Yeates KE; Morton AR
Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
[TBL] [Abstract][Full Text] [Related]
32. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
Hori M
Future Cardiol; 2013 Mar; 9(2):163-76. PubMed ID: 23463968
[TBL] [Abstract][Full Text] [Related]
33. Vasopressin excess and hyponatremia.
Pham PC; Pham PM; Pham PT
Am J Kidney Dis; 2006 May; 47(5):727-37. PubMed ID: 16632011
[TBL] [Abstract][Full Text] [Related]
34. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Verbalis JG
Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
[TBL] [Abstract][Full Text] [Related]
35. Vasopressin and Vasopressin Antagonists in Heart Failure.
Vishram-Nielsen JK; Gustafsson F
Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
[TBL] [Abstract][Full Text] [Related]
36. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
[TBL] [Abstract][Full Text] [Related]
37. [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Dabrowska MD; Krysiak R; Okopień B
Wiad Lek; 2012; 65(1):19-30. PubMed ID: 22827112
[TBL] [Abstract][Full Text] [Related]
38. [Current options of treatment of hyponatremia].
Tesař V
Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
[TBL] [Abstract][Full Text] [Related]
39. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
Goldsmith SR
Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
